Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660.
This is a major milestone in Rebiotix’s efforts to bring the first microbiota-based therapeutic to the market to treat people that have recurrent Clostridioides difficile infection (rCDI).…
Rebiotix is highlighted in The Future of Healthcare series under the headline The Future of Healthcare: “In the future we might be able to take microbes from a healthy person and using them to cure sick people” With Lee Jones, CEO of Rebiotix Inc.…
Rebiotix, Inc., Announces Its Acquisition
Minneapolis, MN, April 9, 2018 — Sofia Fund, a leading angel investment firm focused on high-growth, women-led early stage companies, today announced that its portfolio company, Rebiotix, Inc., is being acquired by Ferring Holding, Inc.,…